REVATIO 20 MG
SILDENAFIL (SILDENAFIL CITRATE) : 20 MG · DIN 02279401 · BGP PHARMA ULC
Health Canada status: MARKETED
What is REVATIO?
REVATIO 20 MG contains SILDENAFIL (SILDENAFIL CITRATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02279401, held by BGP PHARMA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Sep-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02279401 |
|---|---|
| Brand name | REVATIO |
| Generic / active ingredient | SILDENAFIL (SILDENAFIL CITRATE) : 20 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02KX ANTIHYPERTENSIVES FOR PULMONARY ARTERIAL HYPERTENSION |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Sep-2023 |
| Original market date | 2006-06-12 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C02KX ANTIHYPERTENSIVES FOR PULMONARY ARTERIAL HYPERTENSION. 5 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-SILDENAFIL R | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02469669 |
| PMS-SILDENAFIL R | 20 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02412179 |
| REVATIO | 0.8 MG | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 02341611 |
| TEVA-SILDENAFIL R | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02319500 |
| APO-SILDENAFIL R | 20 MG | TABLET | APOTEX INC | DORMANT | DIN 02418118 |
| FINASTERIDE | 5 MG | TABLET | MELIAPHARM INC | CANCELLED POST MARKET | DIN 02348888 |
| SILDENAFIL R | 20 MG | TABLET | METHAPHARM INC | APPROVED | DIN 02450968 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.